Tesamorelin is FDA-approved and sermorelin is not. Tesamorelin holds an active approval for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, while sermorelin's approval was withdrawn in 2009 after the manufacturer discontinued it for commercial reasons, not safety ones.
Tesamorelin and sermorelin are both GHRH analogs that stimulate the pituitary to release its own growth hormone. They differ in three ways that matter clinically: peptide length, regulatory status, and the depth of the evidence behind them. Tesamorelin is FDA-approved for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. Sermorelin has no current FDA approval and is available only as a compounded medication.
- Tesamorelin is a modified GHRH(1-44) analog; sermorelin is GHRH(1-29), the shortest fully active fragment [1][5]
- Tesamorelin is FDA-approved for one narrow indication: HIV-associated lipodystrophy in adults [1]
- Sermorelin's approval was withdrawn effective June 2009 for commercial reasons, not safety [6]
- Tesamorelin has large phase 3 trials; sermorelin's adult evidence base is far smaller [2][3][4]
- Neither is FDA-approved for general anti-aging, body composition, or performance use
The Structural Difference
Endogenous GHRH is a 44-amino-acid peptide. The two drugs take opposite approaches to working with it.
Sermorelin is a 29-amino-acid analog of human GHRH and the shortest synthetic peptide retaining full biological activity [5]. It is the minimum viable fragment, commonly written as GHRH(1-29) [7].
Tesamorelin keeps the full chain and stabilizes it instead. The label describes it as comprising the 44 amino acid sequence of human GRF with a hexenoyl moiety, a C6 chain with a double bond at position 3, attached to the tyrosine residue at the N-terminal [1]. That modification confers resistance to degradation by dipeptidyl peptidase-4 [8], the enzyme that rapidly clears native GHRH, which gives tesamorelin a longer functional half-life.
| Property | Sermorelin | Tesamorelin |
|---|---|---|
| Peptide length | 29 amino acids [5] | 44 amino acids plus N-terminal modification [1] |
| Mechanism | GHRH receptor agonist | GHRH receptor agonist |
| DPP-4 resistance | No structural modification | Yes, from the added moiety [8] |
| FDA status | Approval withdrawn 2009 [6] | Approved 2010, currently marketed [1] |
| Approved indication | None currently | Excess abdominal fat in HIV lipodystrophy, adults [1] |
| How it is obtained | Compounded via 503A or 503B pharmacy | Commercial prescription product |
What the Evidence Shows for Each
This is the largest practical difference between them. Tesamorelin was studied in large randomized placebo-controlled phase 3 programs because it was pursued through FDA approval. Sermorelin never was, for adult use.
Tesamorelin trial results
In a randomized placebo-controlled trial of 412 patients over 26 weeks, visceral adipose tissue fell 15.2% with tesamorelin versus a 5.0% increase on placebo, and IGF-1 rose 81.0% versus a 5.0% decrease [2]. A pooled analysis of two phase 3 trials covering 806 patients found a 15.4% treatment effect on visceral fat at 26 weeks, extending to 17.5% at 52 weeks [3]. A separate 404-patient trial reported a 10.9% visceral fat reduction at 6 months, with reaccumulation after discontinuation [4].
Visceral fat reaccumulated when tesamorelin was stopped [4]. GHRH-analog therapy suppresses a process rather than permanently resetting it, which is relevant to anyone planning a fixed-length course.
Sermorelin evidence
The adult data is much thinner. The most cited controlled study gave [[Nle27]GHRH(1-29)NH2, a norleucine-substituted analog of the same fragment, at 10 mcg/kg subcutaneously nightly for 16 weeks to adults aged 55 to 71](https://pubmed.ncbi.nlm.nih.gov/9141536/) [9], finding IGF-1 elevation within 2 weeks, increased nocturnal GH and skin thickness in both sexes, and increased lean body mass in men. Fat mass did not change significantly over that window. Sermorelin's formal approval history was in pediatric growth hormone deficiency, at 30 mcg/kg subcutaneously at bedtime [5], not adult body composition.
Why Sermorelin Lost Its Approval
This point is frequently misrepresented, so it is worth stating precisely. EMD Serono notified the FDA in 2008 that it was discontinuing Geref, and the FDA withdrew approval of the applications effective June 18, 2009. The agency later determined that the products were not withdrawn from sale for reasons of safety or effectiveness [6]. The withdrawal was a commercial decision, driven by recombinant human growth hormone taking over the pediatric market.
The practical consequence is that sermorelin today is compounded rather than manufactured as an approved finished drug. Quality then depends on the compounding pharmacy, which is why 503A versus 503B sourcing and USP 797 sterility standards matter when choosing a provider.
Metabolic Effects and Glucose
Growth hormone opposes insulin, so glucose handling is a fair question for any GH axis therapy. The tesamorelin data is reassuring over a full course. Pooled phase 3 results found no clinically meaningful differences between groups in glucose parameters at weeks 26 and 52 [3]. Reviews describe a modest early rise in HbA1c that was no longer evident by 52 weeks, indicating neutrality with respect to glucose homeostasis over the long term [7]. A dedicated trial in patients with type 2 diabetes found no significant difference in fasting glucose, HbA1c, or insulin response at 12 weeks [10].
Patients with diabetes or impaired fasting glucose starting any GHRH analog should have glucose monitored during the first 3 months, when the transient perturbation is most likely to appear.
Which One Applies to You
For most people reading this, the comparison is less of a choice than it appears. Tesamorelin is prescribed within its approved indication and is priced as a specialty product. Sermorelin is what telehealth platforms actually offer for age-related GH decline.
- Tesamorelin fits patients with HIV-associated lipodystrophy and excess visceral fat, the population it was approved and studied in [1][2]
- Sermorelin is the practical option for adults with documented low or low-normal IGF-1 and symptoms of age-related decline
- Neither is FDA-approved for anti-aging, bodybuilding, or general weight loss
- Both require a baseline IGF-1 and a 90-day retest to judge response honestly
Frequently Asked Questions
Is tesamorelin stronger than sermorelin?
Tesamorelin has a longer functional half-life because its structure resists degradation by dipeptidyl peptidase-4 [8], and it produced large IGF-1 increases in trials, with IGF-1 rising 81.0% versus placebo over 26 weeks [2]. Sermorelin is cleared more quickly. No head-to-head trial has compared the two directly, so calling one stronger is an inference from separate studies rather than a measured comparison.
Is tesamorelin FDA approved and sermorelin not?
Yes. Tesamorelin was approved in 2010 for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy [1]. Sermorelin previously held FDA approval as Geref, but the manufacturer discontinued it in 2008 and the approval was withdrawn effective June 18, 2009. The FDA determined the withdrawal was not for reasons of safety or effectiveness [6].
How much visceral fat does tesamorelin remove?
Results vary by trial. A 412-patient study found a 15.2% reduction in visceral adipose tissue at 26 weeks versus a 5.0% increase on placebo [2]. A pooled analysis of 806 patients found a 15.4% treatment effect at 26 weeks and 17.5% at 52 weeks [3]. A separate 404-patient trial reported 10.9% at 6 months [4]. Visceral fat reaccumulated after treatment stopped [4].
Can I take tesamorelin instead of sermorelin for anti-aging?
Tesamorelin is approved only for HIV-associated lipodystrophy in adults [1]. Prescribing it for age-related body composition goals is off-label, and it is priced as a specialty product rather than a wellness subscription. Telehealth platforms offering GHRH therapy for age-related GH decline almost always dispense compounded sermorelin instead.
Does tesamorelin or sermorelin affect blood sugar?
Growth hormone opposes insulin, so a transient effect is plausible with either. The tesamorelin data shows an early modest rise in HbA1c that resolved, with no clinically meaningful difference in glucose parameters at weeks 26 and 52 [3][7], and no significant change in fasting glucose or HbA1c at 12 weeks in patients with type 2 diabetes [10]. Patients with diabetes should still have glucose monitored during the first 3 months.
Is sermorelin unsafe since the FDA withdrew it?
The withdrawal was not a safety action. The FDA determined explicitly that Geref was not withdrawn from sale for reasons of safety or effectiveness [6]. The manufacturer stopped producing it because recombinant human growth hormone had taken over the pediatric market. The real safety consideration today is not the molecule but the compounding pharmacy, since compounded products are not subject to the same manufacturing oversight as approved finished drugs.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs, 1999. PMID: 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Determination that GEREF (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness Federal Register, 78 FR 14095, 2013. FR Doc. 2013-04827. https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy HIV/AIDS (Auckland), 2011. PMID: 22096409. https://pubmed.ncbi.nlm.nih.gov/22096409/
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial PLoS One, 2017. PMID: 28617838. https://pubmed.ncbi.nlm.nih.gov/28617838/
